Sinovac says its Covid vaccine more effective with longer dosing interval | World News - Hindustan Times
close_game
close_game

Sinovac says its Covid vaccine more effective with longer dosing interval

Reuters |
Jan 18, 2021 06:18 PM IST

The protection rate for 1,394 participants who received doses of either CoronaVac or placebo three weeks apart was nearly 70%, a Sinovac spokesman said.

China's Sinovac Biotech said on Monday that a clinical trial in Brazil showed its Covid-19 vaccine was almost 20 percentage points more effective in a small sub-group of patients who received their two doses longer apart.

Brazilian researchers announced last week that the vaccine's overall efficacy was 50.4% based on results from more than 9,000 volunteers, most of whom received doses 14 days apart, as outlined in the trial protocol.(AP)
Brazilian researchers announced last week that the vaccine's overall efficacy was 50.4% based on results from more than 9,000 volunteers, most of whom received doses 14 days apart, as outlined in the trial protocol.(AP)

The protection rate for 1,394 participants who received doses of either CoronaVac or placebo three weeks apart was nearly 70%, a Sinovac spokesman said.

Brazilian researchers announced last week that the vaccine's overall efficacy was 50.4% based on results from more than 9,000 volunteers, most of whom received doses 14 days apart, as outlined in the trial protocol.

The spokesman said a small number of participants received their second shot late due to a various reasons, without elaborating.

The dosing interval for Covid-19 vaccines has become a hot topic of debate among scientists, regulators and governments.

UK regulators have said a Covid-19 vaccine from AstraZeneca and Oxford University is more effective when there is a longer gap between doses than initially envisaged.

Britain has also decided to allow a longer gap between doses of a Covid-19 vaccine from Pfizer and BioNTech, even though the companies say they only have efficacy data for a shorter period between shots.

The Sinovac spokesman cautioned the robustness of the data from the sub-group was weaker than the 50% result, which is based on the combined data of those receiving doses two or three weeks apart.

While Sinovac's researchers had said early stage trials showed a four-week interval induced the stronger antibody response than two weeks, this is the first time the company has released efficacy data from a Phase III trial with dosing patterns that differ from its trial protocol.

Sinovac has yet to release global results of its Phase III trials, but its Covid-19 vaccine has been approved for emergency use in several countries, including Brazil, Indonesia and Turkey.

Catch every big hit, every wicket with Crickit, a one stop destination for Live Scores, Match Stats, Infographics & much more. Explore now!

See more

Get Current Updates on World News, US News , Hollywood News , Anime and Top Headlines from around the world.

SHARE THIS ARTICLE ON
SHARE
Story Saved
Live Score
OPEN APP
Saved Articles
Following
My Reads
Sign out
New Delhi 0C
Friday, July 19, 2024
Start 14 Days Free Trial Subscribe Now
Follow Us On